

Sonoporation-assisted micelle delivery in subcutaneous glioma-bearing mice evaluated by PET/Fluorescent bi-modal imaging

Estelle Porret,^{1†} Stéphane Hoang,^{2,3†} Caroline Denis,¹ Eric Doris,² Martin Hruby,³ Anthony Novell,¹ Gravel Edmond,^{2,*} Charles Truillet^{1,*}


1. Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 4 place du général Leclerc, 91401, Orsay, France

2. Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France


3. Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague 162 06, Czech Republic

* Corresponding authors: edmond.gravel@cea.fr (Chemistry) and charles.truillet@universite-paris-saclay.fr (Biology/Imaging)

† These authors contributed equally to this work.



Scheme S1. Synthesis of **DA-PEG**. (i) AlLiH_4 , Et_2O , 0°C à room temp., 1.5 h, under N_2 , 81%; (ii) PPh_3 , CBr_4 , DCM , room temp., 1 h, under N_2 , 59%; (iii) NaH , MeO-PEG2000 , THF , room temp., 72 h, 40%.



Scheme S2. Synthesis of **DA-DFO**. (iv) EDCl , NHS , DCM , 14 h, room temp., 90%; (v) DFO mesylate , PBS/THF , 48 h, room temp., 51%.

Supplementary information




Figure S1. Characterization of the nanoparticles with A-C Dynamic light scattering profiles of **A.** pDA-PEG/DFO micelles; **B.** DiD@pDA-PEG/DFO micelles after purification; **C.** DiD@pDA-PEG/DFO micelles after purification, freeze-drying and resuspension in water. **D.** Toxicity of the DiD@pDA-PEG/DFO determined by MTS assay in different cell lines with U-87 MG and B16F10 (murine melanoma cell line). 8 10³ cells per well for each cell lines in 96-well plate were incubated during 24h with different concentration of micelles going to 0.01 to 1 mg mL⁻¹. The control group for this experiment was incubated with phosphate-buffered saline (PBS). To evaluate the impact of toxicity on the tumor cells, staurosporine at a concentration of 1 μM was used as a positive control. Following a 2-hour incubation with the MTS reagent at 37°C, the plate was analyzed using a microplate reader at 490 nm. The control group treated with PBS served as a baseline without any observed toxicity. Cell viability was determined by calculating the percentage of surviving cells relative to the control group. Each experiment was repeated six

Supplementary information

times. Notably, no significant impact on cell survival was observed at any concentration of micelles tested. (***) : $p < 0,001$).




Figure S2. Purification of DiD@pDA-PEG/DFO micelles. A. Hydrodynamic diameter of DiD@pDA-PEG/DFO^[89Zr] micelles dispersed in water (10 mg mL⁻¹, H₂O optimal) measured by DLS. B. HPLC chromatograms detected at 280 nm of the crude DiD@pDA-PEG/DFO^[89Zr] micelles (orange) or after a pre-first purification step by size exclusion using PD-10 (blue). C. Fluorescent spectra of DiD@pDA-PEG/DFO micelles diluted in water (10 mg mL⁻¹, H₂O optimal) between 606 and 795 nm ($\lambda_{exc} = 575$ nm).




Figure S3. DFO, ⁸⁹Zr and ⁸⁹Zr-DFO characterizations. HPLC chromatograms of A. DFO detected at 280 nm or B. ⁸⁹Zr (violet) and ⁸⁹Zr-DFO (green) detected at 511 KeV with a retention time of 3 and 10 min respectively. C. Radio-iTLC chromatograms and D. autoradiography of the ⁸⁹Zr and ⁸⁹Zr-DFO on iTLC-SG using an eluent of acetonitrile : citric acid (20 mM, adjusted at pH 4.9–5.1 with Na₂CO₃ (2M)) = 10:90 v/v.

Supplementary information




Figure S4. Evaluation of the radiolabeling stability of the DiD@pDA-PEG/DFO^[89Zr] micelles incubated at 37 °C in A. PBS, B. mouse plasma and C. mouse serum. Samples were analyzed by radio-iTLC chromatograms obtained right after mixing (0 h) or after 24 h and 48 h of incubations.




Figure S5. *Ex vivo* analyses obtained one week after DiD@pDA-PEG/DFO^[89Zr] micelle injection in mice bearing subcutaneous U87-MG tumors. A. *Ex vivo* biodistribution obtained with or without US exposure. Results are represented as %ID/g mean \pm standard deviation. %ID/g = percentage of injected dose per tissue gram B. Correlation between the accumulation of DiD@pDA-PEG/DFO^[89Zr] micelles into the main organs obtained by biodistribution *ex vivo* and by PET images analyses. Person test was used for correlation evaluation between the activity measurements obtained by the two methods. Pearson correlation coefficient was determined as $r = 0.94$, $p < 0.0001$ ($n = 6$).

Supplementary information




Figure S6. *In vivo* biodistribution of DiD@pDA-PEG/DFO^[89Zr] micelles in subcutaneous U87-MG tumor model. PET (Coronal-upper and axial-lower) and optical images obtained from mice A. without or B. with US at different time points (0 h, 40 min, 4 h, 24 h, 48 h, 72 h and 1 week) after injection of DiD@pDA-PEG/DFO^[89Zr] micelles (150 μL , 10 mg/mL, 113 μCi). The orange arrows indicate the position of the tumors, and the red dot circle shows the enestatic tumor.

Supplementary information




Figure S7. *In vivo* associated with *ex vivo* biodistribution and the main organs images obtained 72 h after $^{89}\text{Zr}/\text{DiD-Mi}$ injection (150 μL , 10 mg/mL, 113 μCi) in mice bearing subcutaneous U87-MG tumors without (upper) or with (lower) US exposure. A. Coronal (upper) and axial (lower) images of mice obtained by PET imaging. B. Axial images of mice obtained by optical imaging. C. Images of the main organs obtained by optical imaging (upper from the left to the right = muscle, spleen and liver, lower = tumors). The orange arrows indicate the position of the tumors and the red dot circle shows the enestatic tumor.




Figure S8. Assessing drug delivery through the DiD release within the tumor microenvironment. A. Representative images from the enestatic tumor one week after the injection of DiD@pDA-PEG/DFO[^{89}Zr] micelles (150 μL , 10 mg/mL, 113 μCi). Bi-photonic scan of whole tumor sections at A. low and B. high magnification with signal from cell nucleus (blue) and micelles (red). C. The quantification of DiD release was conducted within two groups: DiD-Mi alone and DiD-Mi with ultrasound (US) and microbubbles (μB) one tumor slices one week after injection. Fluorescence intensity was measured across six slices obtained from three different tumors derived from three mice. Each slice was divided into 3 distinct areas measuring $0.323 \times 0.323 \mu\text{m}^2$. The fluorescence of DiD was normalized by the number of cells within each slide, providing quantification for the twelve distinguishable areas. Quantification was performed using ImageJ software, and the number of cells per tile was determined through DAPI labeling.

Supplementary information




Figure S9. Experimental setup for sonoporation procedure.




Figure S10. Study design for the longitudinal PET evaluation of DiD@pDA-PEG/DFO[⁸⁹Zr] micelle delivery with and without US-induced sonoporation in mice bearing subcutaneous U87-MG tumors. A. Timeline for the experiments. Human glioma cells (U87-MG, 5.0×10^6) were subcutaneously implanted in both flanks of nude mice. Tumors were allowed to grow for 3 weeks. Then, μB (SonoVue, 50 μL) were intravenously injected followed ($n = 7$) or not ($n = 7$) by US exposure. Four minutes after US ended, DiD@pDA-PEG/DFO[⁸⁹Zr] micelles (150 μL, 10 mg mL⁻¹, 113 μCi) were intravenously injected into the tail vein. Finally, PET ($n = 14$) and optical ($n = 2$) acquisitions were performed at different time points after DiD@pDA-PEG/DFO[⁸⁹Zr] micelle injection. One mouse per group was sacrificed 72 h post injection for histological analysis. B. Number of animals used for the experiment. In total 14 mice were implanted and randomized into 2 groups with ($n = 7$) or without ($n = 7$) US exposure.